

| Package | Price per Dose | Price | |
|---|---|---|---|
| 90 pills | C$1.49 | C$168.26 C$134.61 | |
| 60 pills | C$1.73 | C$130.58 C$104.47 | |
| 30 pills | C$2.51 | C$95.42 C$76.34 | |
| 360 pills | C$1.95 | C$876.55 C$701.24 Free shipping | |
| 180 pills | C$2.11 | C$474.68 C$379.75 Free shipping | |
| 120 pills | C$2.33 | C$349.10 C$279.28 | |
| 90 pills | C$2.53 | C$283.80 C$227.04 | |
| 60 pills | C$2.83 | C$213.47 C$170.77 | |
| 30 pills | C$3.52 | C$133.09 C$106.48 | |
| 180 pills | C$4.04 | C$909.21 C$727.36 Free shipping | |
| 120 pills | C$4.24 | C$635.43 C$508.35 Free shipping | |
| 90 pills | C$4.54 | C$509.85 C$407.88 Free shipping | |
| 60 pills | C$5.00 | C$374.22 C$299.37 Free shipping | |
| 30 pills | C$6.01 | C$226.03 C$180.82 |
Disclaimer: This information is for patients in Canada and is not a substitute for professional medical advice. Consult a pharmacist or physician for personalized guidance.
The following leaflets provide clear, evidence-informed information about benicar. It is presented in plain language with explanations of medical terms in parentheses where helpful.
Benicar is the brand name for olmesartan medoxomil, a prescription medication used to lower high blood pressure (hypertension). Olmesartan medoxomil is the active ingredient in Benicar. It belongs to a class of medicines called angiotensin II receptor blockers (ARBs), which work by blocking a hormone–receptor pathway that raises blood pressure.
In clinical practice, benicar is used to reduce elevated blood pressure, which helps to prevent stroke, heart attack, and kidney problems associated with hypertension. The medication is typically prescribed when lifestyle modifications alone have not achieved adequate blood pressure control or when another antihypertensive agent is needed in combination therapy.
Benicar acts on the renin–angiotensin system, a natural body system that influences blood vessel tone and fluid balance. By blocking the actions of angiotensin II at the AT1 receptor, benicar promotes blood vessel relaxation and lowers resistance in the arteries. This mechanism contributes to lowering blood pressure over time and can help reduce cardiovascular risk associated with hypertension.
Important terminology explained: hypertension means consistently high blood pressure. The renin–angiotensin system is a hormonal system that helps regulate blood pressure and fluid balance. An ARB is a drug class that interrupts this system to exert blood pressure-lowering effects. These explanations support understanding of how benicar functions in the body.
The primary approved indication for benicar is the treatment of essential hypertension, when measured blood pressure remains above the recommended target. The medication is used to help prevent complications related to high blood pressure and to support long-term cardiovascular health. When prescribed, it is typically part of a broader management plan that includes diet, physical activity, and ongoing monitoring.
In some clinical situations, benicar may be used in combination with other antihypertensive agents to achieve better blood pressure control. Combination therapy is common when single-drug therapy does not reach target blood pressure or when additional therapy is desirable to minimize dose-related side effects. The exact combination and dosing are determined by a clinician based on individual risk factors and tolerance.
Off-label or non‑indicated uses, where applicable, may include strategies intended to protect kidney function in certain patients with diabetes or protein in the urine, or to support blood pressure control in specific resistant cases. Such uses depend on clinical judgment and local practice guidelines, and they require careful consideration of benefits and risks. If a physician or pharmacist suggests an off-label use, clear documentation and ongoing monitoring are essential.
When considering any use beyond the approved indications, it is important to obtain explicit advice from a clinician. This information is not a directive for off-label therapy and should not replace medical counsel. If there is any uncertainty, check the official patient leaflet or consult a healthcare professional for guidance tailored to the individual’s health status.
A simple explanation: benicar blocks a receptor that normally constricts blood vessels, allowing the vessels to relax and the blood pressure to come down. This action reduces the work of the heart and can protect organs from hypertension-related damage over time.
A more detailed pharmacological level: olmesartan medoxomil is a prodrug that is converted to its active form after ingestion. The active compound selectively antagonizes the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from binding. This blockage decreases vasoconstriction (narrowing of blood vessels) and suppresses aldosterone release, which lowers salt and water retention. The net effect is decreased peripheral vascular resistance and a fall in blood pressure. The drug’s pharmacokinetics influence the onset and duration of action, with absorption and metabolism shaping how quickly and for how long blood pressure may be affected. (If any pharmacokinetic details need clarification, consult the official leaflet or a pharmacist.)
From a clinical perspective, the ARB class, including benicar, tends to have a favorable tolerability profile compared with some other antihypertensive classes. This is especially relevant for patients who experience cough, edema, or metabolic disturbances with alternative therapies. The precise response to therapy varies among individuals and can depend on kidney function, age, and concurrent medical conditions.
Table: benicar and related agents within the ARB class (uses and notes). The entries summarize common clinical distinctions in a simple format for quick reference. If any detail requires confirmation, consult the official patient resources or a pharmacist.
| Drug name | Typical approved indication | Notable considerations |
|---|---|---|
| Benicar (olmesartan medoxomil) | Hypertension management; single-agent or combination therapy | Generally well tolerated; watch for dizziness, dehydration, or kidney function changes |
| Losartan | Hypertension; certain kidney-protective uses in diabetes | May interact with potassium levels; monitor kidney function and electrolytes |
| Valsartan | Hypertension; heart failure with reduced ejection fraction in specific scenarios | Similar safety profile; adherence to monitoring is advised |
Dosing is individualized based on blood pressure targets, kidney function, and tolerance. A starting dose can be chosen by a clinician, and the dose is titrated over time to achieve adequate blood pressure control. The goal is to reach target blood pressure while minimizing adverse effects.
Benicar is typically taken once daily or in two divided doses, depending on the prescriber’s plan. The tablets are usually swallowed whole with water, with or without food. If a dose is missed, the usual guidance is to take the next scheduled dose as directed by a clinician and to avoid doubling the next dose to make up for a missed one, unless advised otherwise.
Consistency in taking the medication at roughly the same time each day supports stable blood pressure control. If meals influence blood pressure or tolerance in a particular case, clinicians may provide specific instructions regarding meals or timing. Any changes in dosing or administration should be discussed with a pharmacist or physician prior to implementation.
For long-term management, ongoing follow-up is essential. Blood pressure readings, kidney function, and electrolyte levels (such as potassium) are commonly monitored to ensure safe and effective therapy. Therapy adjustments may occur if monitoring reveals changes in health status or in response to other medications.
Key contraindications for benicar include a history of hypersensitivity to olmesartan medoxomil or any component of the product. Also, severe kidney impairment or conditions that predispose to reduced blood pressure with symptoms such as fainting may influence the decision to use this medication. A clinician will evaluate individual risk factors before initiating therapy.
Common adverse effects may include dizziness, headache, and fatigue, particularly when therapy is started or dose is adjusted. Less commonly, some patients may experience changes in kidney function, elevated potassium levels, or intestinal symptoms. If any new or worsening symptoms occur, contact a healthcare professional promptly to determine whether benicar should be continued or adjusted.
Special caution is advised in patients with a history of low blood pressure, dehydration, or certain cardiovascular or kidney conditions. Routine laboratory tests and clinical assessments help identify potential safety concerns early. If pregnancy is possible, discontinue or adjust therapy in consultation with a clinician, as the drug may affect fetal development.
Serious but rare events require urgent medical attention. Seek immediate medical help if severe dizziness, fainting, signs of allergic reaction, or unexplained swelling occur. This information should not replace medical advice; ongoing monitoring and professional guidance remain essential during therapy.
In elderly patients, blood pressure targets may be approached more gradually to minimize the risk of dizziness or falls. Dose adjustments or slower titration may be advised to accommodate age-related changes in pharmacokinetics and concomitant medications. Regular monitoring helps ensure safety and effectiveness in this population.
In patients with kidney disease, the clinician may adjust the regimen based on renal function and electrolyte status. The drug’s impact on kidney function can vary with disease stage and coexisting conditions. Ongoing assessment is essential to maintain safety and efficacy.
Pregnancy and breastfeeding require careful consideration. ARBs, including olmesartan, are generally avoided during pregnancy due to potential risks to fetal development. If pregnancy occurs or is planned, it is essential to discuss alternative therapies with a clinician. If breastfeeding is being considered, discuss suitability and potential exposures with a healthcare professional, as medication can pass into breast milk and affect the infant.
If a patient has a history of swelling (angioedema) or certain blood pressure-related symptoms, these factors should be discussed before initiating benicar. Individual risk profiles influence decision making, and clinicians will tailor recommendations accordingly to support both maternal and fetal health when applicable.
Benicar can interact with other medicines that affect the renin–angiotensin system, potassium levels, or kidney function. Antihypertensive agents used concurrently with benicar may enhance blood pressure lowering effects, necessitating dose adjustments and careful monitoring to avoid hypotension (abnormally low blood pressure).
Non-steroidal anti-inflammatory drugs (NSAIDs), certain diuretics, potassium-sparing agents, and potassium supplements may influence electrolyte balance or kidney function when used with benicar. A clinician will review all current medications to minimize potential interactions and to plan appropriate monitoring.
Food generally does not cause major interactions with benicar, but consistent daily timing and adherence to a prescribed regimen maximize treatment effectiveness. Alcohol consumption may contribute to dizziness or hypotension in some individuals; moderation and discussion with a clinician are advised, particularly during medication initiation or dose changes.
When using benicar, pregnancy status, vaccination history, and existing medical conditions should be communicated to the pharmacist or clinician. If a new medication is prescribed by another provider, inform them that benicar is part of the current antihypertensive plan to prevent unintentional duplication of therapy or adverse interactions.
Store benicar at room temperature, away from moisture and heat, and keep out of reach of children. Do not crush or break extended-release formulations unless explicitly instructed by a healthcare professional. Always follow the storage guidance provided with the medication and by a pharmacist.
When refilling prescriptions, verify the prescribing clinician’s instructions and confirm the correct dose form and strength. Do not share medications with others and do not use benicar beyond the prescribed duration or outside the recommended indications. If a tablet is damaged or a dose is omitted, consult a pharmacist for safe disposal and guidance on the next steps.
For practical adherence, consider setting reminders, using a pill organizer, and maintaining a log of blood pressure readings and any side effects. Regular follow-up visits with a clinician ensure that therapy remains aligned with health goals and personal tolerance. Any major health changes should prompt prompt communication with a healthcare professional.
In the event of a suspected overdose or exposure to a medication error, seek urgent medical assistance. Do not attempt to treat an overdose at home without professional guidance. Emergency contacts and local healthcare resources should be used as needed.
The ARB class includes several medications used to treat hypertension and related conditions. Benicar is one option within this class, with its own pharmacologic profile and clinical considerations. The table below provides a concise comparison to aid understanding of where benicar fits relative to other ARBs.
Notes: The table above offers a snapshot for educational purposes. Individual therapy decisions depend on clinical evaluation, comorbid conditions, and local guidelines. Check with a pharmacist or clinician for personalized information.
The following questions and answers provide practical information for patients considering or currently using benicar. If any information here is unclear, consult a pharmacist or physician for clarification tailored to individual health needs.
Combination therapy is common and may be prescribed to improve blood pressure control. The clinician will assess interactions and tolerance, and may adjust doses accordingly. Avoid adding new medications without professional guidance, as excessive lowering of blood pressure can occur.
Take the missed dose as soon as remembered unless it is almost time for the next scheduled dose. Do not double the dose to make up for a missed tablet unless a clinician advises otherwise. If many hours have passed, contact a pharmacist or physician for instructions.
Moderate alcohol use may enhance the blood pressure-lowering effects in some individuals and could increase dizziness or fainting risk. Discuss your alcohol use with a clinician to receive personalized advice based on the overall treatment plan and health status.
ARBs are generally avoided in pregnancy due to potential risks to fetal development. If pregnancy is planned or suspected, a clinician should be consulted promptly to adjust therapy. Do not discontinue or modify treatment without professional guidance.
Blood pressure reduction often occurs gradually over days to weeks. Some patients may notice changes sooner, while others require longer to achieve target levels. Ongoing monitoring will guide duration and any needed dose adjustments.
Dizziness or lightheadedness can occur when starting therapy or increasing the dose. This effect is usually temporary. If dizziness persists or is severe, seek advice from a healthcare professional to determine whether dose adjustments or additional tests are needed.
Renal function and electrolyte levels, particularly potassium, are commonly monitored during therapy. Changes can occur with ARB use, especially in patients with preexisting kidney disease or dehydration. Regular laboratory testing helps detect and address issues early.
Benicar can be used for long-term blood pressure management under medical supervision. Periodic assessment of blood pressure, kidney function, and electrolyte balance is typically recommended to ensure continued safety and effectiveness.
Allergic reactions require immediate medical attention. Seek urgent help if symptoms such as swelling of the face or throat, severe rash, or trouble breathing occur. Inform the healthcare professional about any known drug allergies.
Some supplements, including those that affect blood pressure or electrolyte levels, may interact with benicar. It is important to inform a healthcare professional about all vitamins, minerals, and herbal products being used to assess potential interactions and safety concerns.
Store benicar as directed on the product label, away from moisture and heat. Do not use expired medication. If disposal or recycling is required, follow local guidelines or ask a pharmacist for disposal instructions to minimize environmental impact.
Regular checkups with a clinician are advised to monitor blood pressure, kidney function, and electrolytes. Patients should report side effects, signs of low blood pressure, or unusual symptoms between visits. Blood pressure targets and treatment plans may be updated based on monitoring results.
Switching between ARBs is sometimes done to optimize blood pressure control or tolerability. A clinician will consider the patient’s current regimen, prior responses, and any adverse effects before making a change. The transition typically involves gradual dose adjustments and monitoring.
Some non-prescription medicines can interact with ARBs. This includes certain decongestants, pain relievers, and potassium supplements. Always inform a pharmacist about all medications being used, including over‑the‑counter products, to ensure safety and compatibility.
Official patient information leaflets are provided with the medication by the pharmacy or can be requested from a pharmacist or prescribing clinician. These documents contain precise dosing, contraindications, and safety details specific to the product version supplied in Canada.
14–21 days. Free from C$287.05 .
5–9 days. C$43.06
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
